MSTN and proximal spinal muscular atrophy: Driven by the high unmet need for enhanced treatment in SMA and given the body of data on taldefgrobep—including its demonstrated inhibition of myostatin and activin A in muscle, preclinical data and an extensive safety profile in healthy adults and pediatric participants with neuromuscular disease—investigators initiated the RESILIENT clinical trial (NCT05337553) in 2022 [61].